Overview

A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma

Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find out the highest possible dose of maprotiline that can be given safely in combination with temozolomide and tamoxifen.
Phase:
Phase 1
Details
Lead Sponsor:
University of Rochester
Treatments:
Maprotiline
Tamoxifen
Temozolomide